Cwm LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 2.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,854 shares of the medical research company’s stock after selling 94 shares during the period. Cwm LLC’s holdings in IQVIA were worth $698,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently modified their holdings of IQV. Bishop Rock Capital L.P. increased its position in shares of IQVIA by 14,549.4% in the second quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock worth $18,667,000 after purchasing an additional 4,022,902 shares during the period. CIBC Private Wealth Group LLC bought a new position in IQVIA in the second quarter valued at about $182,868,000. State Street Corp grew its position in IQVIA by 3.8% in the second quarter. State Street Corp now owns 8,622,096 shares of the medical research company’s stock valued at $1,870,909,000 after acquiring an additional 315,751 shares during the last quarter. Artemis Investment Management LLP grew its position in IQVIA by 77.6% in the second quarter. Artemis Investment Management LLP now owns 552,506 shares of the medical research company’s stock valued at $120,138,000 after acquiring an additional 241,433 shares during the last quarter. Finally, Amundi grew its position in IQVIA by 11.3% in the second quarter. Amundi now owns 2,078,718 shares of the medical research company’s stock valued at $440,687,000 after acquiring an additional 211,026 shares during the last quarter. Institutional investors own 86.20% of the company’s stock.
IQVIA Price Performance
IQVIA stock opened at $221.53 on Thursday. The stock’s 50 day moving average is $211.12 and its 200 day moving average is $211.02. The company has a debt-to-equity ratio of 2.29, a current ratio of 0.90 and a quick ratio of 0.90. The firm has a market cap of $41.15 billion, a P/E ratio of 36.08, a P/E/G ratio of 2.16 and a beta of 1.37. IQVIA Holdings Inc. has a one year low of $165.75 and a one year high of $263.95.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on IQV shares. StockNews.com started coverage on IQVIA in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Cowen started coverage on IQVIA in a research report on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 target price on the stock. Barclays lifted their target price on IQVIA from $215.00 to $235.00 and gave the company an “overweight” rating in a research report on Thursday, October 27th. Cowen initiated coverage on IQVIA in a research note on Tuesday, December 6th. They set an “outperform” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut their price target on IQVIA from $290.00 to $270.00 in a research note on Tuesday, October 18th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $257.13.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.